TYME-19 / Syros - LARVOL DELTA

TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections (Businesswire) - "Tyme Technologies, Inc....announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19....We believe that TYME-19 diminishes the ability of COVID-19 to hijack an infected cell. TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19."

Patent • Infectious Disease • Novel Coronavirus Disease

TYME Provides Business Update and Announces Second Quarter Fiscal 2021 Financial and Operating Results (Businesswire) - "Continue to advance enrollment in TYME-88-Panc pivotal study; primarily because of unpredictable pandemic-related delays, full enrollment and data readout are not expected before calendar year 2022; Continue to advance enrollment in the HopES Sarcoma Phase II Trial; expect data readout in calendar year 2021; Continue to advance enrollment in PanCAN’s Precision PromiseSM adaptive randomized Phase II/III registration-intent trial in patients with pancreatic cancer using oral SM-88 in second-line monotherapy; expect data readout in calendar year 2022; Publish preclinical findings on TYME-19; Initiate plans for SM-88 clinical programs into other tumor types potentially including metastatic breast, recurrent prostate and/or hematological cancers; Present and/or publish data from Part 1 of TYME-88-Panc study; Continue proof-of-concept and IND-enabling activities for TYME-18; Evaluate opportunity in PanCAN’s Precision PromiseSM adaptive Phase II/III trial..."

Clinical data • Enrollment status • New trial • Preclinical • Breast Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Oncology • Pancreatic Cancer • Prostate Cancer • Sarcoma

Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020 (Businesswire) - “Tyme Technologies, Inc…announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cancer cell metabolism, SM-88 (racemetyrosine) late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD™ trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in prostate, breast and hematological cancers.”

Clinical • Breast Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Infectious Disease • Novel Coronavirus Disease • Oncology • Pancreatic Cancer • Prostate Cancer • Sarcoma

Tyme Technologies to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020 (Businesswire) - "Tyme Technologies, Inc…announced that its leadership will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020. The Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cell metabolism, SM-88 (racemetyrosine) pivotal and late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in pancreatic, prostate, breast and hematological cancers."

Clinical data • New trial • Breast Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Infectious Disease • Novel Coronavirus Disease • Oncology • Pancreatic Cancer • Prostate Cancer • Sarcoma

TYME’s Oncology Research Reveals Potential New Oral Therapy TYME-19 in the Fight Against COVID-19 (Businesswire) - "The proof-of-concept trial is expected to start as soon as customary trial site approvals are completed....TYME and its collaborating partners at Massachusetts General Hospital and Weill Cornell Medical Center are initiating a proof-of-concept study to evaluate TYME-19 versus placebo in newly diagnosed, symptomatic patients with defined high-risk factors. The trial will measure specific indicators of safety and efficacy, including time to resolution of symptoms, changes in viral load, rate of hospitalization and others."

New trial • Infectious Disease • Novel Coronavirus Disease